Eisai said on Wednesday its Alzheimer’s drug Leqembi will launch in Japan on Dec. 20 following its inclusion on the National Health Insurance price list. Intravenous treatment of the drug, co-developed with U.S. partner Biogen, will cost about 2.98 million yen ($20,438) per patient per year, based on a Japanese health ministry panel ruling the same day.
About the Author
